Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin Dose Optimization in HAIC plus TKI for Advanced Hepatocellular Carcinoma
NCT04687163Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 24 months. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04687163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687163.